New Approaches to Protecting Kidneys in Type 1 Diabetes

Kidney disease is one of the most serious long-term complications of Type 1 diabetes. It remains a leading cause of kidney failure and increases the risk of heart and blood vessel disease.

Researchers have identified three main ways that Type 1 diabetes harms the kidneys. First, high blood sugar directly injures kidney tissue. Second, diabetes changes how blood flows through the kidney's filtering units, causing them to work too hard—a problem called hyperfiltration. Third, inflammatory and scarring processes develop in the kidney tissue, driven partly by a system called mineralocorticoid receptor signaling.

Three main types of medications are being investigated for kidney protection in Type 1 diabetes. These include sodium-glucose cotransporter-inhibitors (SGLT2 inhibitors), incretin receptor agonists (which include GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists), and finerenone.

Each of these medication classes works on a different part of the kidney damage process. Some address high blood sugar stress, others help normalize blood flow through the kidneys, and some reduce inflammation and scarring.

The understanding of how these medications protect kidneys has grown rapidly. Clinical trials are generating evidence that these therapies can help, and early results are encouraging enough that doctors are beginning to consider using them alongside standard Type 1 diabetes care.

This expanding knowledge supports the idea that adding these kidney-protective medicines to treatment plans may become an important part of managing Type 1 diabetes and preventing kidney complications.

As research continues, these adjunctive therapies—medications used alongside standard treatments—may become more commonly incorporated into how Type 1 diabetes is managed. The goal is to prevent or slow kidney disease before it becomes a serious problem.

If you have Type 1 diabetes and questions about kidney health or newer treatment options, talk with your healthcare team about what might be right for you.

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.